FDA grants fast track status to novel inhaled therapy for IPF

The U.S. Food and Drug Administration (FDA) has given fast track designation to LTI-03, an inhaled therapy candidate that Rein Therapeutics is developing for idiopathic pulmonary fibrosis (IPF). Fast track status is intended to facilitate the development and review of drugs that treat serious conditions and address unmet medical needs. It allows for more frequent […] The post FDA grants fast track…